Rituximab for treatment of inhibitors in haemophilia a: A phase II study

Thrombosis and Haemostasis

Volumn 112, Issue 3, 2014, Pages 445-458

  Leissinger, Cindy ^a   Josephson, Cassandra D ^b,q   Granger, Suzanne ^c   Konkle, Barbara A ^d   Kruse Jarres, Rebecca ^a   Ragni, Margaret V ^e   Journeycake, Janna M ^f   Valentino, Leonard ^g   Key, Nigel S ^h   Gill, Joan C ⁱ   McCrae, Keith R ^j   Neufeld, Ellis J ^k   Manno, Catherine ^l   Raffini, Leslie ^m   Saxena, Kapil ⁿ   Torres, Marcela ^o   Marder, Victor ^p   Bennett, Carolyn M ^q   Assmann, Susan F ^c  

^a TULANE UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW ENGLAND RESEARCH INSTITUTES   (United States)

^d PUGET SOUND BLOOD CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g RUSH UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF NORTH CAROLINA   (United States)

ⁱ BLOOD RESEARCH INSTITUTE   (United States)

^j LERNER RESEARCH INSTITUTE   (United States)

^k HARVARD UNIVERSITY   (United States)

^l NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^m CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

ⁿ UNIVERSITY OF OKLAHOMA   (United States)

^o Children's Medical Center   (United States)

^p JOINT REPLACEMENT INSTITUTE   (United States)

^q EMORY UNIVERSITY   (United States)

more..

Author keywords

Anti CD20; Antibodies; Blood coagulation inhibitor; CD20 antibody; Haemophilia A; Monoclonal; Murine derived

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BLOOD CLOTTING FACTOR 8 INHIBITOR; RITUXIMAB; BLOCKING ANTIBODY; BLOOD CLOTTING FACTOR 8; CD20 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ALLERGIC REACTION; ANEMIA; ANOREXIA; ANTIBODY TITER; ARTHRALGIA; ARTICLE; ASTHMA; BACTERIAL ARTHRITIS; BELL PALSY; BLEEDING; CATHETER INFECTION; CHILD; CLINICAL ARTICLE; CONJUNCTIVITIS; CONTINUOUS INFUSION; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; FEVER; FOLLOW UP; FRACTURE; HEAD INJURY; HEADACHE; HEMATURIA; HEMOPHILIA A; HERPES ZOSTER; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOTENSION; IMMUNOLOGICAL TOLERANCE; LETHARGY; LEUKOCYTOSIS; LUNG INFECTION; MALE; MALLORY WEISS SYNDROME; NAUSEA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUESTIONNAIRE; SEPSIS; SINGLE BLIND PROCEDURE; SINUSITIS; STREPTOCOCCUS INFECTION; SUBDURAL HEMATOMA; VIRUS MENINGITIS; VOMITING; ANTIBODY PRODUCTION; BLOOD CLOTTING; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM; MULTICENTER STUDY; PRESCHOOL CHILD; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY FORMATION; ANTIGENS, CD20; BLOOD COAGULATION; CHILD; CHILD, PRESCHOOL; FACTOR VIII; FOLLOW-UP STUDIES; HEMOPHILIA A; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; RITUXIMAB; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84907270053     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-01-0078     Document Type: Article

References (38)

1. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-435.
2. Gouw SC, van der Bom JG, Ljung R, et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368: 231-239.
3. Hay CR, Ludlam CA, Colvin BT, et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 1998; 79: 762-766.
4. Ewenstein BM, Gomperts ED, Pearson S, et al. Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF/Bioclate): a prospective pharmacovigilance study. Haemophilia 2004; 10: 491-498.
5. Gringeri A, Mantovani LG, Scalone L, et al. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-2363.
6. Morfini M, Haya S, Tagariello G, et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606–612.
7. Soucie JM, Cianfrini C, Janco RL, et al. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood 2004; 103: 2467-2473.
8. Hay CRM, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335–1344.
9. Mariani G, Kroner B. International immune tolerance registry, 1997 update. Vox Sang 1999; 77 (Suppl 1): 25-27.
10. DiMichele DM, Kroner BL; The North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52-57.
11. Lenk H. The German Registry of immune tolerance treatment in hemophilia--1999 update. Haematologica 2000; 85 (10 Suppl): 45-47.
12. Haya S, López MF, Aznar JA, et al. Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry. Haemophilia 2001; 7: 154-159.
13. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four doses treatment program. J Clin Oncol 1998; 16: 2825-2833.
14. Barcellini W, Zaja F, Zaninoni A, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood 2012; 119: 3691-3697.
15. Froissart A, Buffet M, Veyradier A, et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med 2012; 40: 104-111.
16. Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007; 110: 2924-2930.
17. Ahmed AR, Spigelman Z, Cavacini LA, et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355: 1772-1779.
18. Smith KG, Jones RB, Burns SM, et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006; 54: 2970-2982.
19. Franchini M. Rituximab in the treatment of adult acquired hemophilia A: a systematic review. Crit Rev Oncol Hematol 2007; 63: 47–52.
20. Huth-Kühne A, Baudo F, Collins P, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 2009; 94: 566–575.
21. Boles JC, Key NS, Kasthuri R, et al. Single-center experience with rituximab as first-line immunosuppression for acquired hemophilia. J Thromb Haemost 2011; 9: 1429-1431.
22. Collins P, Baudo F, Knoebl P, et al. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood 2012; 120: 47–55.
23. Linde R, Escuriola Ettinghausen C, Voigt B, et al. First successful inhibitor elimination with a new protocol in a high responding hemophilia A – patient after failure of various immune tolerance induction regimens. Blood 2001; 98: 534a.
24. Medeiros BC, Geraghty S, Stabler SP. Improved response to immune tolerance therapy for factor VIII inhibitor after rituximab therapy. Blood 2002; 100: 103b.
25. Pruthi RK, Schmidt KA, Slaby JA, et al. Rituximab in treatment of high titer FVIII inhibitor in congenital hemophilia A. Blood 2002; 100: 104b.
26. Fox RA, Neufeld EJ, Bennett CM. Rituximab for adolescents with haemophilia and high titre inhibitors. Haemophilia 2006; 12: 218-222.
27. Mateo J, Badell I, Forner R, et al. Successful suppression using Rituximab of a factor VIII inhibitor in a boy with severe congenital haemophilia: an example of a significant decrease of treatment costs. Thromb Haemost 2006; 95: 386-387.
28. Moschovi M, Aronis S, Trimis G, et al. Rituximab in the treatment of high responding inhibitors in severe haemophilia A. Haemophilia 2006; 12: 95-99.
29. Carcao M, St Louis J, Poon MC, et al. Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience. Haemophilia 2006; 12: 7–18.
30. Mathias M, Khair K, Hann I, et al. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia. Br J Haematol 2004; 125: 366-368.
31. Collins P, Mathias M, Hanley Jet al. Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort. J Thromb Haemost 2009; 7: 787-794.
32. Franchini M, Mengoli C, Lippi G, et al. Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients’ analysis. Haemophilia 2008; 14: 903–912.
33. Chuansumrit A, Husapadol S, Wongwerawattanakoon P, et al. Rituximab as an adjuvant therapy to immune tolerance in a haemophilia A boy with high inhibitor titre Haemophilia 2007; 13: 108-110.
34. Chang H, Sher GD, Blanchette VS, et al. The impact of inhibitors on the cost of clotting factor replacement therapy in Haemophilia A in Canada. Haemophilia 1999; 5: 247-252.
35. Goudemand J. Pharmaco-economic aspects of inhibitor treatment. Eur J Haematol Suppl 1998; 63: 24-27.
36. Globe DR, Cunningham WE, Andersen R, et al. The Hemophilia Utilization Group Study (HUGS): determinants of costs of care in persons with haemophilia A. Haemophilia 2003; 9: 325-331.
37. Tony HP, Burmester G, Schulze-Koops H, et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 2011; 13: R75.
38. Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol 2010; 47: 187-189.